Essayer OR - Gratuit
Eyeing 20-20 Vision of Excellence
BioSpectrum Asia
|BioSpectrum Asia Jan 2025
Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research
-
A native of Ahmedabad and an expert in the field of drug development, Dr Jogin Desai incorporated his startup Eyestem Research in India, back in 2015, aiming to democratise access to cell therapy through a scalable cell therapy platform.
The journey of Eyestem started when Dr Desai met ophthalmologist Dr Rajani Battu (currently the Chief Medical Officer at Eyestem), in 2015, for a medical appointment that changed everything for both of them. Following the appointment, Dr Rajani introduced him to patients diagnosed with degenerative diseases of the eye and the terrible suffering they have to endure. He realised that dry age-related macular degeneration (AMD) is the largest cause of incurable blindness in the world for patients over 50 years. And this meant that for 196 million people suffering from this disease around the world, 40 million of which are in India, finding a cure is a need of the hour.
Eyestem, as a company, was initiated in late 2015 by Dr Jogin Desai, Dr Rajani Battu and Dr Dhruv Sareen, with a small project handed to a research team led by Dr Rajarshi Pal, then at Manipal Institute of Regenerative Medicine. A year later, Dr Desai approached Centre for Cellular and Molecular Platforms, C-CAMP, in Bengaluru, with the intention to incubate considering the state-of-the-art cell culture facilities and diverse funding and mentoring programmes available at C-CAMP. Dr Rajarshi Pal joined as a Co-Founder to incubate and lead the science.
Cette histoire est tirée de l'édition BioSpectrum Asia Jan 2025 de BioSpectrum Asia.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE BioSpectrum Asia
BioSpectrum Asia
Leadgene Biosolutions expands product portfolio for metabolic research
Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Korea, Philippines to develop nextgeneration tuberculosis diagnosis
The Korea National Institute of Health (NIH), under the Korea Disease Control and Prevention Agency (KDCA) is entering into a research agreement with the Research Institute for Tropical Medicine (RITM) of the Philippines to initiate an international collaborative research project aimed at developing next-generation tuberculosis (TB) diagnostic technologies.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia and Indonesia achieve WHO Listed Authority status in medical products regulation
The World Health Organization (WHO) has formally recognised the regulatory authorities for medical products of Australia and Indonesia as WHO Listed Authorities (WLAs), an achievement that underscores growing global confidence in regulatory systems across diverse regions and income settings.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Aevice Health announces expansion into Australian market
AeviceMD Monitoring System, a non-invasive wearable respiratory monitoring solution developed by Singapore-based Aevice Health, has been included in the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Insilico Medicine lists on Hong Kong Stock Exchange, exhibiting largest Hong Kong biotech IPO
Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia provides cheaper medicines for inflammatory & rare liver disease and MS
Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis (MS) will pay less for newly Pharmaceutical Benefits Scheme (PBS) listed medicines, as directed by the Australian Government.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Valneva and Serum Institute of India discontinue Chikungunya vaccine license agreement
France-based Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Santhera licenses AGAMREE to Nxera Pharma in $205 M Asia-Pacific deal
Swiss firm Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK for the development, manufacturing and commercialisation of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
AdCella and Shanghai Cell Therapy Group launch global collaboration for cancer therapy
Australia-based AdAlta, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.
1 min
BioSpectrum Asia Feb 2026
Listen
Translate
Change font size
